StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 4/21/2014, (NASDAQ:OPTR), $12.78 0.00, 0.00%, "HOLD" Optimer Pharmaceu Stock
 




  
  

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   4/21/2014   StockRing.com recommends to   "HOLD"   OPTR   stock at current price of   $12.78.
Today OPTR stock opened at $N/A and was trading in the daily range of $ N/A - N/A per share.
Optimer Pharmaceu (NASDAQ:OPTR) Market capitalization is $N/A. OPTR average daily volume is 1,433,510.
On last trading session OPTR stock traded shares. Also the Short Ratio for (NASDAQ:OPTR) stock is N/A.
Last year Optimer Pharmaceu(NASDAQ:OPTR) before taxes (EBITDA) (ttm) earned $0 on revenue of $0.
OPTR 50-Day Moving Average is $12.69 vs. $12.78 now and 200-Day Moving Average is $13.76 vs. $12.78.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "BUY".  S&P 500 is "BUY" on  4/17/2014
--------------------------------------------------------------------------------------------------------------------
OPTR Earnings Per Share - EPS (ttm) is 0. OPTR Stock Price Per Earnings ratio - P/E is N/A.
Optimer Pharmaceu(NASDAQ:OPTR) stock pays a dividend of $0.00 per share which is a yield of N/A%.
On average analysts predict that One Year Target Estimated price for OPTR stock is $14.
In the last 52 weeks OPTR stock was trading in the range of $8.64 - 16.80.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4459 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 4/17/2014 1:36:28 AM
2. DOW30+    Part 2    192 Stocks    Updated: 4/17/2014 1:50:47 AM
3. DOW30+    Part 3    193 Stocks    Updated: 4/17/2014 1:55:09 AM
4. DOW30+    Part 4    195 Stocks    Updated: 4/17/2014 1:59:27 AM
 
5. ENERGY    Part 1    188 Stocks    Updated: 4/18/2014 10:46:27 AM
6. ENERGY    Part 2    186 Stocks    Updated: 4/18/2014 10:51:32 AM
7. ENERGY    Part 3    196 Stocks    Updated: 4/18/2014 10:56:58 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 4/16/2014 2:02:40 AM
9. HEALTH    Part 2    138 Stocks    Updated: 4/16/2014 2:07:27 AM
 
10. FINANCE    Part 1    191 Stocks    Updated: 11/13/2013 10:58:43 AM
11. FINANCE    Part 2    193 Stocks    Updated: 11/13/2013 12:29:31 PM
12. FINANCE    Part 3    188 Stocks    Updated: 11/13/2013 12:42:47 PM
13. FINANCE    Part 4    188 Stocks    Updated: 11/13/2013 12:46:35 PM
14. FINANCE    Part 5    190 Stocks    Updated: 11/13/2013 10:52:57 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 11/12/2013 11:38:45 PM
16. SERVICE    Part 2    186 Stocks    Updated: 11/12/2013 11:43:21 PM
17. SERVICE    Part 3    183 Stocks    Updated: 11/12/2013 11:48:07 PM
18. SERVICE    Part 4    193 Stocks    Updated: 11/12/2013 11:53:13 PM
 
19. TECH    Part 1    187 Stocks    Updated: 4/17/2014 11:25:01 PM
20. TECH    Part 2    183 Stocks    Updated: 4/17/2014 11:29:45 PM
21. TECH    Part 3    185 Stocks    Updated: 4/17/2014 11:34:24 PM
22. TECH    Part 4    102 Stocks    Updated: 4/17/2014 11:37:10 PM
 
23. IPOs    200 Stocks    Updated: 4/18/2014 7:17:48 PM
 
24. ETFs    Part 1    200 Stocks    Updated: 11/18/2013 12:58:25 AM
25. ETFs    Part 2    200 Stocks    Updated: 11/18/2013 1:04:02 AM
26. ETFs    Part 3    6 Stocks    Updated: 11/18/2013 1:10:14 AM

BUY  DOW 30+:    ENERGY: CDW  CBA  TSRE  QIWI  EIGI     HEALTH: EWN  EPP  NYC  TOK  IWW 
      FINANCE: XHB  XLI  SHM  XTN  GURU     SERVICES: BRAQ  ASEA  MLPJ  CHIM  PERM     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: GGB     ENERGY: MKTO  Q  HASI  SRLP  TSC     HEALTH: GNMA 
      FINANCE: ICOL  LEDD  JJG  GREK  VXX     SERVICES: CNPF     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

BUY  DOW 30+:    ENERGY: WPT  WBB  VOYA  VMEM  TSRE     HEALTH: VEGI  USMV  URTH  TZY  TZW 
      FINANCE: XVZ  XTN  XSW  XRT  XPH     SERVICES: PERM  MLPJ  CHIM  BRAQ  ASEA     TECH: WDC  SWIR  RENN  ONNN  NTAP 
SELL  DOW 30+: GGB     ENERGY: XON  XGTI  UBIC  TSC  TNDM     HEALTH: GNMA 
      FINANCE: VXX  SGG  SGAR  LEDD  JJG     SERVICES: CNPF     TECH: YNDX  XRX  XLNX  WIT  WCC 

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



4/21/2014  Monday, April 21, 2014 (Irvine, California) Today StockRing.com Recommendation is to "HOLD"for Optimer Pharmaceu (NASDAQ:OPTR) Stock. OPTR stock opening price was $12.66 per share. Current price of NASDAQ:OPTR Stock is $12.78 per share and it is $0.00, (0.00%) today and it was trading in the daily range of $12.62 - 12.89 per share. Current Bid Price for (NASDAQ:OPTR) stock is $0.00 and the Ask Price is $0.00. In the last 52 weeks OPTR stock was trading in the range of $8.64 - 16.80. 50-Day Moving Average for (NASDAQ:OPTR) stock is $12.69 and 200-Day Moving Average is $13.76. On average analysts predict that One Year Target Estimated price for (NASDAQ:OPTR) stock is $14.

Optimer Pharmaceu (NASDAQ:OPTR) is rated as a "HOLD" in the last 3 months. For Daily Updated ratings call: (800) 656-4210.

Optimer Pharmaceu (NASDAQ:OPTR) Market capitalization is $N/A. (NASDAQ:OPTR) stock average daily volume is 1,433,510 shares per day. However, on last trading session of Oct 23, 2012 OPTR stock traded shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:OPTR) stock is N/A. On previous trading session OPTR Stock closed at $12.78 per share.

Last year Optimer Pharmaceu (NASDAQ:OPTR) before taxes (EBITDA) (ttm) earned $0 on total revenue of $0. Earnings Per Share - EPS (ttm) for OPTR stock is 0. Thus, (NASDAQ:OPTR) Stock Price/Sales (ttm) ratio is N/A and Price/Book (mrq) ratio is N/A.

(NASDAQ:OPTR) Stock does NOT PAY any dividend. So at this time (NASDAQ:OPTR) Stock maintains Trailing Annual Dividend Rate at 0.00 .


StockRing Recommendations for Optimer Pharmaceu (NASDAQ:OPTR) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=OPTR

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:OPTR Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/21/2014 1 Year Stock market price chart for Optimer Pharmaceu (NASDAQ:OPTR) Stock on Monday, April 21, 2014
  
1 Year OPTR 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
4/21/2014 5 days Stock market price chart for Optimer Pharmaceu (NASDAQ:OPTR) Stock on Monday, April 21, 2014
  
5 Days OPTR 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:OPTR Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/21/2014 Stock market price quote data for Optimer Pharmaceu (NASDAQ:OPTR) Stock on Monday, April 21, 2014

Last Trade: 12.78
Trade Time: Oct 23
Change: 0.00, (0.00%)
Prev Close: 12.78
Open: 12.66
Bid: 0.00
Ask: 0.00
1y Target Est: $14
50-Day Moving Average: 12.69
200-Day Moving Average:
13.76
Short Ratio: N/A
Trailing Annual Dividend Rate: 0.00
Day's Range: 12.62 - 12.89
52wk Range: 8.64 - 16.80
Volume:
Avg Vol: 1,433,510
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): 0
Div & Yield: 0.00 (N/A%)
Revenue (ttm): 0
Earnings before Tax (EBITDA) (ttm): 0
Price/Sales (ttm): N/A
Price/Book (mrq): N/A
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs



4/21/2014 Latest stock market news data for Optimer Pharmaceu (NASDAQ:OPTR) Stock on Monday, April 21, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Motley Fool - Apr 4, 2014
It acquired Trius Therapeutics and Optimer Pharmaceuticals last summer for $1.6 billion, adding Sivextro to its portfolio in addition to Dificid, Optimer's infectious diarrhea treatment. The company plans to spend $400 million just this year in ...
PPD Adds Experienced Leader to Enhance Delivery of Innovative Solutions
MarketWatch - 24 minutes ago
Most recently, he served as head of business development, corporate strategy and international teams at Optimer Pharmaceuticals. De Silva holds degrees in finance, economics and engineering from Stanford University, London School of Economics and ...
FDA panel endorses Cubist antibiotic
Boston Globe - Apr 1, 2014
At the time of the Trius takeover, Cubist said it was also buying Optimer Pharmaceuticals Inc. of Jersey City, N.J., a smaller company that developed its own antibacterial drug, Dificid.
Deadly Bowel Infection Draws Drugmakers Seeking Cures
Bloomberg - Apr 13, 2014
Cubist acquired its Dificid drug when it bought Optimer Pharmaceuticals Inc. for at least $535 million last year. Argent now takes that when prescribed antibiotics to reduce the risk of another infection, she said.
Double Dip: Doctors Paid to Advise, Promote Drug Companies That Fund Their ...
ProPublica - Mar 25, 2014
He co-wrote a 2011 research study, published in the New England Journal of Medicine, about the antibiotic Dificid with employees of its maker, Optimer Pharmaceuticals - a company purchased by Cubist last fall. According to the most recent disclosure ...
Durata Therapeutics: Gains Ahead
Seeking Alpha - Apr 2, 2014
Also Dalbavancin only compliments their current portfolio of treatments for acute bacterial skin diseases and is in line with their recent acquisitions of Trius Therapeutics (TSRX) and Optimer Pharmaceuticals (OPTR). Cubist is also faced with trouble ...
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
NASDAQ - Mar 26, 2014
Some recent acquisitions/deals include Shire's ( SHPG ) acquisition of ViroPharma, Salix's ( SLXP ) acquisition of Santarus as well as the acquisition of Optimer Pharmaceuticals and Trius Therapeutics by Cubist Pharmaceuticals ( CBST ) and that of Elan ...
Pharma Biotech Stock Outlook - March 2014 - Zacks.com
Touro College Orthopedic Physical Therapy Residency Program Receives ...
Physical Therapy Products - Mar 28, 2014
The Orthopedic Physical Therapy Residency Program (OPTR) at Touro College, New York, NY, has received credentialing from the American Physical Therapy Association (APTA), which has ended a year-long process.
Zacks Industry Outlook Highlights: Eli Lilly, AstraZeneca, Shire, Salix and ...
DigitalJournal.com - Mar 27, 2014
Some recent acquisitions/deals include Shire's (Nasdaq:SHPG-Free Report) acquisition of ViroPharma, Salix's (Nasdaq:SLXP-Free Report) acquisition of Santarus as well as the acquisition of Optimer Pharmaceuticals and Trius Therapeutics by Cubist ...

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   


CSX Earnings Plow Through the Polar Vortex
Zacks.com
CSX estimates that weather-related disruptions increased expenses by approximately six cents per share, and impacted revenue contribution by about two to three cents. On the positive, management has seen the demand for core railroad products increase ...

and more »

Durata Therapeutics: Gains Ahead
Seeking Alpha
To justify those estimated revenues further, Cubist Pharmaceuticals has 2014 U.S. revenue guidance for Cubicin at $970 - $1,020 million, with a similar market share as Durata's target market share. While CBST was not producing these revenues ... Also ...

and more »

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

OPTR rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


4/21/2014 News from StockRing Blog about Optimer Pharmaceu (NASDAQ:OPTR) Stock on Monday, April 21, 2014



Copyright © 2012 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.